Omega-3 fatty acid ethyl esters do not improve clopidogrel associated P2Y12 inhibition in stroke patients

The specific action of omega-3 fatty acid ethyl esters (OFA) in preventing cerebrovascular disease remains unknown, but research has demonstrated multiple possible mechanisms. In addition to altering lipid profiles, OFA may inhibit platelet aggregation. Clopidogrel inhibits platelets via the P2Y12 r...

Full description

Bibliographic Details
Main Authors: Ping Li, Haris Kamal, Melissa Baxter, Bijal K. Mehta
Format: Article
Language:English
Published: MDPI AG 2015-06-01
Series:Neurology International
Subjects:
Online Access:http://www.pagepress.org/journals/index.php/ni/article/view/5809
_version_ 1797936837140938752
author Ping Li
Haris Kamal
Melissa Baxter
Bijal K. Mehta
author_facet Ping Li
Haris Kamal
Melissa Baxter
Bijal K. Mehta
author_sort Ping Li
collection DOAJ
description The specific action of omega-3 fatty acid ethyl esters (OFA) in preventing cerebrovascular disease remains unknown, but research has demonstrated multiple possible mechanisms. In addition to altering lipid profiles, OFA may inhibit platelet aggregation. Clopidogrel inhibits platelets via the P2Y12 receptor. OFA may alter clopidogrel-associated platelet-inhibition via a possible combined effect on P2Y12 inhibition. To determine if OFA affects clopidogrel associated P2Y12 platelet receptor inhibition by comparing the percentage of responders in patients with cerebrovascular disease who were taking clopidogrel with or without OFA. We retrospectively reviewed data from adult patients with cerebrovascular disease or cerebral aneurysms and taking clopidogrel, who were seen at a single hospital between March 2010 to September 2011. We included 438 subjects in the study. For the 67 subjects who received loading doses of both clopidogrel and OFA, 71.6% had a P2Y12 inhibition response more than 20%, which is considered a positive response. For the 55 subjects who received just clopidogrel load, 67.2% of subjects were responders. There were 70.4% responders in the 274 subjects who were taking 75 mg of clopidogrel alone at home, and 73.8% responders in the 42 subjects who were taking both clopidogrel and OFA at home. However, these percentage differences were not statistically significant. This study did not find additional P2Y12 platelet inhibition when patients were given OFA, either given as a loading dose or taking it daily.
first_indexed 2024-04-10T18:35:36Z
format Article
id doaj.art-8c7457d27f07468786a0736db9854216
institution Directory Open Access Journal
issn 2035-8385
2035-8377
language English
last_indexed 2024-04-10T18:35:36Z
publishDate 2015-06-01
publisher MDPI AG
record_format Article
series Neurology International
spelling doaj.art-8c7457d27f07468786a0736db98542162023-02-02T01:44:04ZengMDPI AGNeurology International2035-83852035-83772015-06-017110.4081/ni.2015.58093081Omega-3 fatty acid ethyl esters do not improve clopidogrel associated P2Y12 inhibition in stroke patientsPing Li0Haris Kamal1Melissa Baxter2Bijal K. Mehta3Department of Neurology, Jacob Neurological Institute, University at Buffalo, NYDepartment of Neurology, Jacob Neurological Institute, University at Buffalo, NYDepartment of Pharmacy, Buffalo General Medical Center, University at Buffalo, NYDepartment of Neurology, David Geffen School of Medicine, University of California Los Angeles, Harbor-UCLA Medical Center, Torrance, CAThe specific action of omega-3 fatty acid ethyl esters (OFA) in preventing cerebrovascular disease remains unknown, but research has demonstrated multiple possible mechanisms. In addition to altering lipid profiles, OFA may inhibit platelet aggregation. Clopidogrel inhibits platelets via the P2Y12 receptor. OFA may alter clopidogrel-associated platelet-inhibition via a possible combined effect on P2Y12 inhibition. To determine if OFA affects clopidogrel associated P2Y12 platelet receptor inhibition by comparing the percentage of responders in patients with cerebrovascular disease who were taking clopidogrel with or without OFA. We retrospectively reviewed data from adult patients with cerebrovascular disease or cerebral aneurysms and taking clopidogrel, who were seen at a single hospital between March 2010 to September 2011. We included 438 subjects in the study. For the 67 subjects who received loading doses of both clopidogrel and OFA, 71.6% had a P2Y12 inhibition response more than 20%, which is considered a positive response. For the 55 subjects who received just clopidogrel load, 67.2% of subjects were responders. There were 70.4% responders in the 274 subjects who were taking 75 mg of clopidogrel alone at home, and 73.8% responders in the 42 subjects who were taking both clopidogrel and OFA at home. However, these percentage differences were not statistically significant. This study did not find additional P2Y12 platelet inhibition when patients were given OFA, either given as a loading dose or taking it daily.http://www.pagepress.org/journals/index.php/ni/article/view/5809Omega-3 fatty acidclopidogrelP2Y12 receptorcerebrovascular diseasestrokeDHAEPA
spellingShingle Ping Li
Haris Kamal
Melissa Baxter
Bijal K. Mehta
Omega-3 fatty acid ethyl esters do not improve clopidogrel associated P2Y12 inhibition in stroke patients
Neurology International
Omega-3 fatty acid
clopidogrel
P2Y12 receptor
cerebrovascular disease
stroke
DHA
EPA
title Omega-3 fatty acid ethyl esters do not improve clopidogrel associated P2Y12 inhibition in stroke patients
title_full Omega-3 fatty acid ethyl esters do not improve clopidogrel associated P2Y12 inhibition in stroke patients
title_fullStr Omega-3 fatty acid ethyl esters do not improve clopidogrel associated P2Y12 inhibition in stroke patients
title_full_unstemmed Omega-3 fatty acid ethyl esters do not improve clopidogrel associated P2Y12 inhibition in stroke patients
title_short Omega-3 fatty acid ethyl esters do not improve clopidogrel associated P2Y12 inhibition in stroke patients
title_sort omega 3 fatty acid ethyl esters do not improve clopidogrel associated p2y12 inhibition in stroke patients
topic Omega-3 fatty acid
clopidogrel
P2Y12 receptor
cerebrovascular disease
stroke
DHA
EPA
url http://www.pagepress.org/journals/index.php/ni/article/view/5809
work_keys_str_mv AT pingli omega3fattyacidethylestersdonotimproveclopidogrelassociatedp2y12inhibitioninstrokepatients
AT hariskamal omega3fattyacidethylestersdonotimproveclopidogrelassociatedp2y12inhibitioninstrokepatients
AT melissabaxter omega3fattyacidethylestersdonotimproveclopidogrelassociatedp2y12inhibitioninstrokepatients
AT bijalkmehta omega3fattyacidethylestersdonotimproveclopidogrelassociatedp2y12inhibitioninstrokepatients